Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging

AI Briefing

• – Rubedo Life Sciences announces positive preliminary Phase 1 clinical trial results for RLS-1496 in treating plaque psoriasis, atopic dermatitis, and skin aging.
• – The trial involved a single-center, ascending-dose, randomized, double-blind, vehicle-controlled study in patients with the conditions.
• – Results indicate the potential effectiveness of RLS-1496 in reducing symptoms of psoriasis, atopic dermatitis, and skin aging.